Greene, E., Cutter, G., Muppidi, S., Juel, V., Rodrigues, E., Korideck, H., & Howard, J. (2023). Myasthenia Gravis Activities of Daily Living (MG-ADL) Response to Eculizumab Treatment in Patients from the Generalized Myasthenia Gravis Registry (P1-5.020). In Neurology (Vol. 100). Ovid Technologies (Wolters Kluwer Health). https://doi.org/10.1212/wnl.0000000000202295

Greene, Ericka, Gary Cutter, Srikanth Muppidi, Vern Juel, Ema Rodrigues, Houari Korideck, and James Howard. “Myasthenia Gravis Activities of Daily Living (MG-ADL) Response to Eculizumab Treatment in Patients from the Generalized Myasthenia Gravis Registry (P1-5.020).” In Neurology, Vol. 100. Ovid Technologies (Wolters Kluwer Health), 2023. https://doi.org/10.1212/wnl.0000000000202295.

Greene E, Cutter G, Muppidi S, Juel V, Rodrigues E, Korideck H, et al. Myasthenia Gravis Activities of Daily Living (MG-ADL) Response to Eculizumab Treatment in Patients from the Generalized Myasthenia Gravis Registry (P1-5.020). In: Neurology. Ovid Technologies (Wolters Kluwer Health); 2023.

Greene, Ericka, et al. “Myasthenia Gravis Activities of Daily Living (MG-ADL) Response to Eculizumab Treatment in Patients from the Generalized Myasthenia Gravis Registry (P1-5.020).” Neurology, vol. 100, no. 17_supplement_2, Ovid Technologies (Wolters Kluwer Health), 2023. Crossref, doi:10.1212/wnl.0000000000202295.

Greene E, Cutter G, Muppidi S, Juel V, Rodrigues E, Korideck H, Howard J. Myasthenia Gravis Activities of Daily Living (MG-ADL) Response to Eculizumab Treatment in Patients from the Generalized Myasthenia Gravis Registry (P1-5.020). Neurology. Ovid Technologies (Wolters Kluwer Health); 2023.